Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A1 | P30531 | 2/20 | 0.64 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.64 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.64 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.64 |
| ▸ | SLC6A11 | P48066 | 2/20 | 0.64 |
| ▸ | SLC6A13 | Q9NSD5 | 2/20 | 0.64 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.64 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.64 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ITGB3 | P05106 | 9/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 9/20 | 0.45 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
| ▸ | F2R | P25116 | 4/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29207730 | 1.00 | SLC6A1 (0.64) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL31370174 | 1.00 | SLC6A1 (0.64) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| Hydrochloric Acid SCHEMBL25181844 | 0.98 | SLC6A1 (0.62) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL13308547 | 0.88 | KMT2A (0.62) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL13308548 | 0.88 | KMT2A (0.62) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL5494841 | 0.88 | SLC6A1 (0.60) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL2525645 | 0.88 | KMT2A (0.62) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL954535 | 0.87 | ITGB3 (0.56) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| Hydrochloric Acid SCHEMBL8182632 | 0.86 | KMT2A (0.60) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL5313695 | 0.86 | KMT2A (0.56) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103118540-B | Pesticide containing 2, 5-diketopiperazine derivative as active ingredient | Rural Development Office (KR) | 2016-02-17 | — | — | CN | claimed |
| CN-103118540-A | Pesticide containing 2, 5-diketopiperazine derivative as active ingredient | REPUBLIC KOREA MAN RURAL DEV | 2013-05-22 | — | — | CN | claimed |
| US-12570662-B2 | Substituted pyrrolo[1,2-b]pyridazines as bifunctional degraders of interleukin-1 receptor-associated kinases | NURIX THERAPEUTICS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| EP-4512402-A2 | BIFUNCTIONAL DEGRADERS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND THERAPEUTIC USE THEREOF | Nurix Therapeutics, Inc. (US) | 2025-02-26 | — | — | EP | disclosed |
| EP-4367118-B1 | BIFUNCTIONAL DEGRADERS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND THERAPEUTIC USE THEREOF | NURIX THERAPEUTICS INC (US) | 2025-01-29 | — | — | EP | disclosed |
| US-20240417402-A1 | SUBSTITUTED PYRROLO[1,2-b]PYRIDAZINES AS BIFUNCTIONAL DEGRADERS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES | GILEAD SCIENCES, INC. | 2024-12-19 | — | — | US | disclosed |
| US-20240279202-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING ITK, COMPOSITIONS, COMPRISING THE SAME METHODS OF THEIR MAKING AND METHODS OF THEIR USE | NURIX THERAPEUTICS, INC. | 2024-08-22 | — | — | US | disclosed |
| EP-4367118-A1 | BIFUNCTIONAL DEGRADERS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND THERAPEUTIC USE THEREOF | Nurix Therapeutics, Inc. (US) | 2024-05-15 | — | — | EP | disclosed |
| US-11976071-B2 | Substituted pyrrolo[1,2-b]pyridazines as bifunctional degraders of interleukin-1 receptor-associated kinases | GILEAD SCIENCES, INC. (US) | 2024-05-07 | — | — | US | disclosed |
| CN-117813307-A | Difunctional degradants of interleukin-1 receptor related kinase and therapeutic uses thereof | 新锐思生物制药股份有限公司 | 2024-04-02 | — | — | CN | disclosed |
| EP-4334303-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING ITK, COMPOSITIONS, COMPRISING THE SAME METHODS OF THEIR MAKING AND METHODS OF THEIR USE | Nurix Therapeutics, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| CN-103118540-B | Pesticide containing 2, 5-diketopiperazine derivative as active ingredient | Rural Development Office (KR) | 2016-02-17 | — | — | CN | disclosed |
| CN-103118540-A | Pesticide containing 2, 5-diketopiperazine derivative as active ingredient | REPUBLIC KOREA MAN RURAL DEV | 2013-05-22 | — | — | CN | disclosed |
| US-20070238721-A1 | Highly Selective Novel Amidation Method | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-10-11 | — | — | US | disclosed |
| EP-1753752-A1 | HIGHLY SELECTIVE NOVEL AMIDATION METHOD | Takeda Pharmaceutical Company Limited (JP) | 2007-02-21 | — | — | EP | disclosed |
| WO-2005121133-A1 | HIGHLY SELECTIVE NOVEL AMIDATION METHOD | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-12-22 | — | — | WO | disclosed |
| EP-1129070-A4 | NEUROTROPHIC DIAMIDE AND CARBAMATE AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2005-03-02 | — | — | EP | disclosed |
| EP-1129070-A1 | NEUROTROPHIC DIAMIDE AND CARBAMATE AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-09-05 | — | — | EP | disclosed |
| US-6228872-B1 | PEPTIDE-PROLYL ISOMERASE AND ROTAMASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2001-05-08 | — | — | US | disclosed |
| WO-2000027811-A1 | NEUROTROPHIC DIAMIDE AND CARBAMATE AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570662-B2 | Substituted pyrrolo[1,2-b]pyridazines as bifunctional degraders of interleukin-1 receptor-associated kinases | IRAK1, IRAK2, IRAK4 | SLC6A1 4401/4885GABRA5 2737/4885GABRB2 2473/4885 |
| US-20240279202-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING ITK, COMPOSITIONS, COMPRISING THE SAME METHODS OF THEIR MAKING AND METHODS OF THEIR USE | ITK, NFATC1, TNIK | SLC6A1 4732/4885GABRA5 4199/4885GABRB2 2531/4885 |
| US-20240417402-A1 | SUBSTITUTED PYRROLO[1,2-b]PYRIDAZINES AS BIFUNCTIONAL DEGRADERS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES | IRAK1, IRAK2, IRAK4 | SLC6A1 4787/4885GABRA5 2108/4885GABRB2 2224/4885 |
| US-20070238721-A1 | Highly Selective Novel Amidation Method | NAAA, CPS1, COASY | SLC6A1 3877/4885GABRA5 2173/4885GABRB2 2186/4885 |
| US-11976071-B2 | Substituted pyrrolo[1,2-b]pyridazines as bifunctional degraders of interleukin-1 receptor-associated kinases | IRAK1, IRAK2, IRAK4 | SLC6A1 4583/4885GABRA5 1276/4885GABRB2 1582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.